542 results on '"Henrik Clausen"'
Search Results
2. Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate
- Author
-
Elena Ethel Vidal-Calvo, Anne Martin-Salazar, Swati Choudhary, Robert Dagil, Sai Sundar Rajan Raghavan, Lara Duvnjak, Mie Anemone Nordmaj, Thomas Mandel Clausen, Ann Skafte, Jan Oberkofler, Kaituo Wang, Mette Ø Agerbæk, Caroline Løppke, Amalie Mundt Jørgensen, Daria Ropac, Joana Mujollari, Shona Willis, Agnès Garcias López, Rebecca Louise Miller, Richard Torbjörn Gustav Karlsson, Felix Goerdeler, Yen-Hsi Chen, Ana R. Colaço, Yong Wang, Thomas Lavstsen, Agnieszka Martowicz, Irina Nelepcu, Mona Marzban, Htoo Zarni Oo, Maj Sofie Ørum-Madsen, Yuzhuo Wang, Morten A. Nielsen, Henrik Clausen, Michael Wierer, Dominik Wolf, Ismail Gögenur, Thor G. Theander, Nader Al-Nakouzi, Tobias Gustavsson, Mads Daugaard, and Ali Salanti
- Subjects
Science - Abstract
Abstract Molecular similarities between embryonic and malignant cells can be exploited to target tumors through specific signatures absent in healthy adult tissues. One such embryonic signature tumors express is oncofetal chondroitin sulfate (ofCS), which supports disease progression and dissemination in cancer. Here, we report the identification and characterization of phage display-derived antibody fragments recognizing two distinct ofCS epitopes. These antibody fragments show binding affinity to ofCS in the low nanomolar range across a broad selection of solid tumor types in vitro and in vivo with minimal binding to normal, inflamed, or benign tumor tissues. Anti-ofCS antibody drug conjugates and bispecific immune cell engagers based on these targeting moieties disrupt tumor progression in animal models of human and murine cancers. Thus, anti-ofCS antibody fragments hold promise for the development of broadly effective therapeutic and diagnostic applications targeting human malignancies.
- Published
- 2024
- Full Text
- View/download PDF
3. Binding of Akkermansia muciniphila to mucin is O-glycan specific
- Author
-
Janneke Elzinga, Yoshiki Narimatsu, Noortje de Haan, Henrik Clausen, Willem M. de Vos, and Hanne L. P. Tytgat
- Subjects
Science - Abstract
Abstract The intestinal anaerobic bacterium Akkermansia muciniphila is specialized in the degradation of mucins, which are heavily O-glycosylated proteins that constitute the major components of the mucus lining the intestine. Despite that adhesion to mucins is considered critical for the persistence of A. muciniphila in the human intestinal tract, our knowledge of how this intestinal symbiont recognizes and binds to mucins is still limited. Here, we first show that the mucin-binding properties of A. muciniphila are independent of environmental oxygen concentrations and not abolished by pasteurization. We then dissected the mucin-binding properties of pasteurized A. muciniphila by use of a recently developed cell-based mucin array that enables display of the tandem repeats of human mucins with distinct O-glycan patterns and structures. We found that A. muciniphila recognizes the unsialylated LacNAc (Galβ1-4GlcNAcβ1-R) disaccharide selectively on core2 and core3 O-glycans. This disaccharide epitope is abundantly found on human colonic mucins capped by sialic acids, and we demonstrated that endogenous A. muciniphila neuraminidase activity can uncover the epitope and promote binding. In summary, our study provides insights into the mucin-binding properties important for colonization of a key mucin-foraging bacterium.
- Published
- 2024
- Full Text
- View/download PDF
4. Structure and function of Semaphorin-5A glycosaminoglycan interactions
- Author
-
Gergely N. Nagy, Xiao-Feng Zhao, Richard Karlsson, Karen Wang, Ramona Duman, Karl Harlos, Kamel El Omari, Armin Wagner, Henrik Clausen, Rebecca L. Miller, Roman J. Giger, and E. Yvonne Jones
- Subjects
Science - Abstract
Abstract Integration of extracellular signals by neurons is pivotal for brain development, plasticity, and repair. Axon guidance relies on receptor-ligand interactions crosstalking with extracellular matrix components. Semaphorin-5A (Sema5A) is a bifunctional guidance cue exerting attractive and inhibitory effects on neuronal growth through the interaction with heparan sulfate (HS) and chondroitin sulfate (CS) glycosaminoglycans (GAGs), respectively. Sema5A harbors seven thrombospondin type-1 repeats (TSR1-7) important for GAG binding, however the underlying molecular basis and functions in vivo remain enigmatic. Here we dissect the structural basis for Sema5A:GAG specificity and demonstrate the functional significance of this interaction in vivo. Using x-ray crystallography, we reveal a dimeric fold variation for TSR4 that accommodates GAG interactions. TSR4 co-crystal structures identify binding residues validated by site-directed mutagenesis. In vitro and cell-based assays uncover specific GAG epitopes necessary for TSR association. We demonstrate that HS-GAG binding is preferred over CS-GAG and mediates Sema5A oligomerization. In vivo, Sema5A:GAG interactions are necessary for Sema5A function and regulate Plexin-A2 dependent dentate progenitor cell migration. Our study rationalizes Sema5A associated developmental and neurological disorders and provides mechanistic insights into how multifaceted guidance functions of a single transmembrane cue are regulated by proteoglycans.
- Published
- 2024
- Full Text
- View/download PDF
5. Identification of global inhibitors of cellular glycosylation
- Author
-
Daniel Madriz Sørensen, Christian Büll, Thomas D. Madsen, Erandi Lira-Navarrete, Thomas Mandel Clausen, Alex E. Clark, Aaron F. Garretson, Richard Karlsson, Johan F. A. Pijnenborg, Xin Yin, Rebecca L. Miller, Sumit K. Chanda, Thomas J. Boltje, Katrine T. Schjoldager, Sergey Y. Vakhrushev, Adnan Halim, Jeffrey D. Esko, Aaron F. Carlin, Ramon Hurtado-Guerrero, Roberto Weigert, Henrik Clausen, and Yoshiki Narimatsu
- Subjects
Science - Abstract
Here, the authors discover small molecules that inhibit glycosylation processes that occur in the Golgi apparatus of cells. The molecules reversibly inhibit formation of elaborate glycan structures without affecting secretion of glycoproteins.
- Published
- 2023
- Full Text
- View/download PDF
6. Structural and mechanistic insights into the cleavage of clustered O-glycan patches-containing glycoproteins by mucinases of the human gut
- Author
-
Víctor Taleb, Qinghua Liao, Yoshiki Narimatsu, Ana García-García, Ismael Compañón, Rafael Junqueira Borges, Andrés Manuel González-Ramírez, Francisco Corzana, Henrik Clausen, Carme Rovira, and Ramon Hurtado-Guerrero
- Subjects
Science - Abstract
AM0627 is a bis-O-glycan mucinase that might work in the final steps of mucus degradation, thereby providing a carbon and nitrogen source for Akkermansia muciniphila. Here, the authors provide molecular insights into AM0627 function from X-ray crystallography and computer simulations.
- Published
- 2022
- Full Text
- View/download PDF
7. Human-type sialic acid receptors contribute to avian influenza A virus binding and entry by hetero-multivalent interactions
- Author
-
Mengying Liu, Liane Z. X. Huang, Anthony A. Smits, Christian Büll, Yoshiki Narimatsu, Frank J. M. van Kuppeveld, Henrik Clausen, Cornelis A. M. de Haan, and Erik de Vries
- Subjects
Science - Abstract
It is believed that human Influenza HA glycoprotein attaches to alpha2-6 linked sialic acids (SA) on cells, while avian viruses bind to alpha2-3 linked sialic acids, therewith contributing to host tropism. Here, Liu et al. show that mixing low-affinity alpha2-3 SA with low amounts of high-affinity alpha2-6 SA increases binding and entry of human viruses and the converse for avian virus. This shows that receptor recognition is not as strict as currently assumed and provides evidence that heteromultivalent interactions between human/avian HA and SA contributes to host adaptation.
- Published
- 2022
- Full Text
- View/download PDF
8. Enterovirus D-68 Infection of Primary Rat Cortical Neurons: Entry, Replication, and Functional Consequences
- Author
-
Katrien C. K. Poelaert, Regina G. D. M. van Kleef, Mengying Liu, Arno van Vliet, Heyrhyoung Lyoo, Lora-Sophie Gerber, Yoshiki Narimatsu, Christian Büll, Henrik Clausen, Erik de Vries, Remco H. S. Westerink, and Frank J. M. van Kuppeveld
- Subjects
EV-D68 ,neurotropism ,receptor ,Microbiology ,QR1-502 - Abstract
ABSTRACT Enterovirus D68 (EV-D68) is an emerging pathogen associated with mild to severe respiratory disease. Since 2014, EV-D68 is also linked to acute flaccid myelitis (AFM), causing paralysis and muscle weakness in children. However, it remains unclear whether this is due to an increased pathogenicity of contemporary EV-D68 clades or increased awareness and detection of this virus. Here, we describe an infection model of primary rat cortical neurons to study the entry, replication, and functional consequences of different EV-D68 strains, including historical and contemporary strains. We demonstrate that sialic acids are important (co)receptors for infection of both neurons and respiratory epithelial cells. Using a collection of glycoengineered isogenic HEK293 cell lines, we show that sialic acids on either N-glycans or glycosphingolipids can be used for infection. Additionally, we show that both excitatory glutamatergic and inhibitory GABA-ergic neurons are susceptible and permissive to historical and contemporary EV-D68 strains. EV-D68 infection of neurons leads to the reorganization of the Golgi-endomembranes forming replication organelles, first in the soma and later in the processes. Finally, we demonstrate that the spontaneous neuronal activity of EV-D68-infected neuronal network cultured on microelectrode arrays (MEA) is decreased, independent of the virus strain. Collectively, our findings provide novel insights into neurotropism and -pathology of different EV-D68 strains, and argue that it is unlikely that increased neurotropism is a recently acquired phenotype of a specific genetic lineage. IMPORTANCE Acute flaccid myelitis (AFM) is a serious neurological illness characterized by muscle weakness and paralysis in children. Since 2014, outbreaks of AFM have emerged worldwide, and they appear to be caused by nonpolio enteroviruses, particularly enterovirus-D68 (EV-D68), an unusual enterovirus that is known to mainly cause respiratory disease. It is unknown whether these outbreaks reflect a change of EV-D68 pathogenicity or are due to increased detection and awareness of this virus in recent years. To gain more insight herein, it is crucial to define how historical and circulating EV-D68 strains infect and replicate in neurons and how they affect their physiology. This study compares the entry and replication in neurons and the functional consequences on the neural network upon infection with an old “historical” strain and contemporary “circulating” strains of EV-D68.
- Published
- 2023
- Full Text
- View/download PDF
9. Structural basis for the synthesis of the core 1 structure by C1GalT1
- Author
-
Andrés Manuel González-Ramírez, Ana Sofia Grosso, Zhang Yang, Ismael Compañón, Helena Coelho, Yoshiki Narimatsu, Henrik Clausen, Filipa Marcelo, Francisco Corzana, and Ramon Hurtado-Guerrero
- Subjects
Science - Abstract
The glycosyltransferase C1GalT1 directs a key step in protein O-glycosylation important for the expression of the cancer-associated Tn and T antigens. Here, the authors provide molecular insights into the function of C1GalT1 by solving the crystal structure of the Drosophila enzyme-substrate complex.
- Published
- 2022
- Full Text
- View/download PDF
10. Atomic and Specificity Details of Mucin 1 O‑Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling
- Author
-
Helena Coelho, Matilde de las Rivas, Ana S. Grosso, Ana Diniz, Cátia O. Soares, Rodrigo A. Francisco, Jorge S. Dias, Ismael Compañon, Lingbo Sun, Yoshiki Narimatsu, Sergey Y. Vakhrushev, Henrik Clausen, Eurico J. Cabrita, Jesús Jiménez-Barbero, Francisco Corzana, Ramon Hurtado-Guerrero, and Filipa Marcelo
- Subjects
Chemistry ,QD1-999 - Published
- 2022
- Full Text
- View/download PDF
11. A universal GlycoDesign for lysosomal replacement enzymes to improve circulation time and biodistribution
- Author
-
Yen-Hsi Chen, Weihua Tian, Makiko Yasuda, Zilu Ye, Ming Song, Ulla Mandel, Claus Kristensen, Lorenzo Povolo, André R. A. Marques, Tomislav Čaval, Albert J. R. Heck, Julio Lopes Sampaio, Ludger Johannes, Takahiro Tsukimura, Robert Desnick, Sergey Y. Vakhrushev, Zhang Yang, and Henrik Clausen
- Subjects
glycoengineering ,enzyme replacement therapy ,lysosomal storage disease ,glycoprotein therapeutics ,bioengineering ,Biotechnology ,TP248.13-248.65 - Abstract
Currently available enzyme replacement therapies for lysosomal storage diseases are limited in their effectiveness due in part to short circulation times and suboptimal biodistribution of the therapeutic enzymes. We previously engineered Chinese hamster ovary (CHO) cells to produce α-galactosidase A (GLA) with various N-glycan structures and demonstrated that elimination of mannose-6-phosphate (M6P) and conversion to homogeneous sialylated N-glycans prolonged circulation time and improved biodistribution of the enzyme following a single-dose infusion into Fabry mice. Here, we confirmed these findings using repeated infusions of the glycoengineered GLA into Fabry mice and further tested whether this glycoengineering approach, Long-Acting-GlycoDesign (LAGD), could be implemented on other lysosomal enzymes. LAGD-engineered CHO cells stably expressing a panel of lysosomal enzymes [aspartylglucosamine (AGA), beta-glucuronidase (GUSB), cathepsin D (CTSD), tripeptidyl peptidase (TPP1), alpha-glucosidase (GAA) or iduronate 2-sulfatase (IDS)] successfully converted all M6P-containing N-glycans to complex sialylated N-glycans. The resulting homogenous glycodesigns enabled glycoprotein profiling by native mass spectrometry. Notably, LAGD extended the plasma half-life of all three enzymes tested (GLA, GUSB, AGA) in wildtype mice. LAGD may be widely applicable to lysosomal replacement enzymes to improve their circulatory stability and therapeutic efficacy.
- Published
- 2023
- Full Text
- View/download PDF
12. Role of N-Glycosylation in FcγRIIIa interaction with IgG
- Author
-
Julie Van Coillie, Morten A. Schulz, Arthur E. H. Bentlage, Noortje de Haan, Zilu Ye, Dionne M. Geerdes, Wim J. E. van Esch, Lise Hafkenscheid, Rebecca L. Miller, Yoshiki Narimatsu, Sergey Y. Vakhrushev, Zhang Yang, Gestur Vidarsson, and Henrik Clausen
- Subjects
Fc gamma receptors ,CD16a ,mAbs ,IgG ,glycoengineering ,N-glycosylation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system. The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities. Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation. In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions. We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the key N-glycan features that affected binding affinity. Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
- Published
- 2022
- Full Text
- View/download PDF
13. Display of the human mucinome with defined O-glycans by gene engineered cells
- Author
-
Rebecca Nason, Christian Büll, Andriana Konstantinidi, Lingbo Sun, Zilu Ye, Adnan Halim, Wenjuan Du, Daniel M. Sørensen, Fabien Durbesson, Sanae Furukawa, Ulla Mandel, Hiren J. Joshi, Leo Alexander Dworkin, Lars Hansen, Leonor David, Tina M. Iverson, Barbara A. Bensing, Paul M. Sullam, Ajit Varki, Erik de Vries, Cornelis A. M. de Haan, Renaud Vincentelli, Bernard Henrissat, Sergey Y. Vakhrushev, Henrik Clausen, and Yoshiki Narimatsu
- Subjects
Science - Abstract
Mucins play critical roles in maintaining the human microbiome, with their O-glycosylated tandem repeats (TRs) providing important cues for microbiota. Here, the authors develop a cellular platform for producing TRs with defined O-glycan structures to dissect the functions of TR O-glycosylation.
- Published
- 2021
- Full Text
- View/download PDF
14. Applying transcriptomics to studyglycosylation at the cell type level
- Author
-
Leo Alexander Dworkin, Henrik Clausen, and Hiren Jitendra Joshi
- Subjects
Molecular biology ,Omics ,Transcriptomics ,Science - Abstract
Summary: The complex multi-step process of glycosylation occurs in a single cell, yet current analytics generally cannot measure the output (the glycome) of a single cell. Here, we addressed this discordance by investigating how single cell RNA-seq data can be used to characterize the state of the glycosylation machinery and metabolic network in a single cell. The metabolic network involves 214 glycosylation and modification enzymes outlined in our previously built atlas of cellular glycosylation pathways. We studied differential mRNA regulation of enzymes at the organ and single cell level, finding that most of the general protein and lipid oligosaccharide scaffolds are produced by enzymes exhibiting limited transcriptional regulation among cells. We predict key enzymes within different glycosylation pathways to be highly transcriptionally regulated as regulatable hotspots of the cellular glycome. We designed the Glycopacity software that enables investigators to extract and interpret glycosylation information from transcriptome data and define hotspots of regulation.
- Published
- 2022
- Full Text
- View/download PDF
15. Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models
- Author
-
Diana Canals Hernaez, Michael R. Hughes, Yicong Li, Ilaria Mainero Rocca, Pamela Dean, Julyanne Brassard, Erin M. Bell, Ismael Samudio, Anne-Marie Mes-Masson, Yoshiki Narimatsu, Henrik Clausen, Ola Blixt, Calvin D. Roskelley, and Kelly M. McNagny
- Subjects
podocalyxin ,antibody-drug conjugate ,PODO447 ,tumor-specific ,glycoepitope ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Podocalyxin (Podxl) is a CD34-related cell surface sialomucin that is normally highly expressed by adult vascular endothelia and kidney podocytes where it plays a key role in blocking adhesion. Importantly, it is also frequently upregulated on a wide array of human tumors and its expression often correlates with poor prognosis. We previously showed that, in xenograft studies, Podxl plays a key role in metastatic disease by making tumor initiating cells more mobile and invasive. Recently, we developed a novel antibody, PODO447, which shows exquisite specificity for a tumor-restricted glycoform of Podxl but does not react with Podxl expressed by normal adult tissue. Here we utilized an array of glycosylation defective cell lines to further define the PODO447 reactive epitope and reveal it as an O-linked core 1 glycan presented in the context of the Podxl peptide backbone. Further, we show that when coupled to monomethyl auristatin E (MMAE) toxic payload, PODO447 functions as a highly specific and effective antibody drug conjugate (ADC) in killing ovarian, pancreatic, glioblastoma and leukemia cell lines in vitro. Finally, we demonstrate PODO447-ADCs are highly effective in targeting human pancreatic and ovarian tumors in xenografted NSG and Nude mouse models. These data reveal PODO447-ADCs as exquisitely tumor-specific and highly efficacious immunotherapeutic reagents for the targeting of human tumors. Thus, PODO447 exhibits the appropriate characteristics for further development as a targeted clinical immunotherapy.
- Published
- 2022
- Full Text
- View/download PDF
16. The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells
- Author
-
Weihua Tian, Zilu Ye, Shengjun Wang, Morten Alder Schulz, Julie Van Coillie, Lingbo Sun, Yen-Hsi Chen, Yoshiki Narimatsu, Lars Hansen, Claus Kristensen, Ulla Mandel, Eric Paul Bennett, Siamak Jabbarzadeh-Tabrizi, Raphael Schiffmann, Jin-Song Shen, Sergey Y. Vakhrushev, Henrik Clausen, and Zhang Yang
- Subjects
Science - Abstract
Lysosomal replacement enzymes are taken up by cell surface receptors that recognize glycans, the effects of different glycan features are unknown. Here the authors present a gene engineering screen in CHO cells that allows custom N-glycan-decorated enzymes with improved circulation time and organ distribution.
- Published
- 2019
- Full Text
- View/download PDF
17. The half-life of the bone-derived hormone osteocalcin is regulated through O-glycosylation in mice, but not in humans
- Author
-
Omar Al Rifai, Catherine Julien, Julie Lacombe, Denis Faubert, Erandi Lira-Navarrete, Yoshiki Narimatsu, Henrik Clausen, and Mathieu Ferron
- Subjects
osteocalcin ,glycosylation ,o-linked glycosylation ,half-life ,bone ,plasmin ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Osteocalcin (OCN) is an osteoblast-derived hormone with pleiotropic physiological functions. Like many peptide hormones, OCN is subjected to post-translational modifications (PTMs) which control its activity. Here, we uncover O-glycosylation as a novel PTM present on mouse OCN and occurring on a single serine (S8) independently of its carboxylation and endoproteolysis, two other PTMs regulating this hormone. We also show that O-glycosylation increases OCN half-life in plasma ex vivo and in the circulation in vivo. Remarkably, in human OCN (hOCN), the residue corresponding to S8 is a tyrosine (Y12), which is not O-glycosylated. Yet, the Y12S mutation is sufficient to O-glycosylate hOCN and to increase its half-life in plasma compared to wildtype hOCN. These findings reveal an important species difference in OCN regulation, which may explain why serum concentrations of OCN are higher in mouse than in human.
- Published
- 2020
- Full Text
- View/download PDF
18. Cell-Based Glycan Arrays—A Practical Guide to Dissect the Human Glycome
- Author
-
Christian Büll, Hiren J. Joshi, Henrik Clausen, and Yoshiki Narimatsu
- Subjects
Science (General) ,Q1-390 - Abstract
Summary: Exploring the biological functions of the human glycome is highly challenging given its tremendous structural diversity. We have developed stable libraries of isogenic HEK293 cells with loss or gain of glycosylation features that together form the cell-based glycan array, a self-renewable resource for the display of the human glycome in the natural context. This protocol describes the use of the cell-based glycan array for dissection of molecular interactions and biological functions of glycans using a wide range of biological assays.For complete details on the use and execution of this protocol, please refer to (Narimatsu et al., 2019).
- Published
- 2020
- Full Text
- View/download PDF
19. Structural and Mechanistic Insights into the Catalytic-Domain-Mediated Short-Range Glycosylation Preferences of GalNAc-T4
- Author
-
Matilde de las Rivas, Earnest James Paul Daniel, Helena Coelho, Erandi Lira-Navarrete, Lluis Raich, Ismael Compañón, Ana Diniz, Laura Lagartera, Jesús Jiménez-Barbero, Henrik Clausen, Carme Rovira, Filipa Marcelo, Francisco Corzana, Thomas A. Gerken, and Ramon Hurtado-Guerrero
- Subjects
Chemistry ,QD1-999 - Published
- 2018
- Full Text
- View/download PDF
20. Direct quality control of glycoengineered erythropoietin variants
- Author
-
Tomislav Čaval, Weihua Tian, Zhang Yang, Henrik Clausen, and Albert J. R. Heck
- Subjects
Science - Abstract
Several therapeutics are glycosylated proteins, yet the analysis of their specific glycosylation patterns remains challenging. Here the authors demonstrate an approach for the detailed characterization of glycosylated biopharmaceuticals applied to the determination of the glycoproteoform profile of glycoengineered variants of erythropoietin.
- Published
- 2018
- Full Text
- View/download PDF
21. The interdomain flexible linker of the polypeptide GalNAc transferases dictates their long-range glycosylation preferences
- Author
-
Matilde de las Rivas, Erandi Lira-Navarrete, Earnest James Paul Daniel, Ismael Compañón, Helena Coelho, Ana Diniz, Jesús Jiménez-Barbero, Jesús M. Peregrina, Henrik Clausen, Francisco Corzana, Filipa Marcelo, Gonzalo Jiménez-Osés, Thomas A. Gerken, and Ramon Hurtado-Guerrero
- Subjects
Science - Abstract
GalNAc transferases’ (GalNAc-Ts) catalytic domains are connected to a lectin domain through a flexible linker. Here the authors present a structural analysis of GalNAc-T4 that implicates the linker region as modulator of the orientations of the lectin domain, which in turn imparts substrate specificity.
- Published
- 2017
- Full Text
- View/download PDF
22. Polypeptide N-acetylgalactosaminyltransferase-Associated Phenotypes in Mammals
- Author
-
Kentaro Kato, Lars Hansen, and Henrik Clausen
- Subjects
polypeptide N-acetylgalactosaminyltransferase ,UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase ,GalNAc-T ,GALNT ,O-glycosylation ,Organic chemistry ,QD241-441 - Abstract
Mucin-type O-glycosylation involves the attachment of glycans to an initial O-linked N-acetylgalactosamine (GalNAc) on serine and threonine residues on proteins. This process in mammals is initiated and regulated by a large family of 20 UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts) (EC 2.4.1.41). The enzymes are encoded by a large gene family (GALNTs). Two of these genes, GALNT2 and GALNT3, are known as monogenic autosomal recessive inherited disease genes with well characterized phenotypes, whereas a broad spectrum of phenotypes is associated with the remaining 18 genes. Until recently, the overlapping functionality of the 20 members of the enzyme family has hindered characterizing the specific biological roles of individual enzymes. However, recent evidence suggests that these enzymes do not have full functional redundancy and may serve specific purposes that are found in the different phenotypes described. Here, we summarize the current knowledge of GALNT and associated phenotypes.
- Published
- 2021
- Full Text
- View/download PDF
23. A conserved major facilitator superfamily member orchestrates a subset of O-glycosylation to aid macrophage tissue invasion
- Author
-
Katarina Valoskova, Julia Biebl, Marko Roblek, Shamsi Emtenani, Attila Gyoergy, Michaela Misova, Aparna Ratheesh, Patricia Reis-Rodrigues, Kateryna Shkarina, Ida Signe Bohse Larsen, Sergey Y Vakhrushev, Henrik Clausen, and Daria E Siekhaus
- Subjects
invasion ,T antigen ,metastasis ,O-glycosylation ,major facilitator superfamily ,macrophage ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Aberrant display of the truncated core1 O-glycan T-antigen is a common feature of human cancer cells that correlates with metastasis. Here we show that T-antigen in Drosophila melanogaster macrophages is involved in their developmentally programmed tissue invasion. Higher macrophage T-antigen levels require an atypical major facilitator superfamily (MFS) member that we named Minerva which enables macrophage dissemination and invasion. We characterize for the first time the T and Tn glycoform O-glycoproteome of the Drosophila melanogaster embryo, and determine that Minerva increases the presence of T-antigen on proteins in pathways previously linked to cancer, most strongly on the sulfhydryl oxidase Qsox1 which we show is required for macrophage tissue entry. Minerva’s vertebrate ortholog, MFSD1, rescues the minerva mutant’s migration and T-antigen glycosylation defects. We thus identify a key conserved regulator that orchestrates O-glycosylation on a protein subset to activate a program governing migration steps important for both development and cancer metastasis.
- Published
- 2019
- Full Text
- View/download PDF
24. Drosophila O-GlcNAcase Mutants Reveal an Expanded Glycoproteome and Novel Growth and Longevity Phenotypes
- Author
-
Ilhan Akan, Adnan Halim, Sergey Y. Vakhrushev, Henrik Clausen, and John A. Hanover
- Subjects
O-GlcNAc proteome ,growth ,short life span ,HCF ,KISMET ,SIN3A ,Cytology ,QH573-671 - Abstract
The reversible posttranslational O-GlcNAc modification of serine or threonine residues of intracellular proteins is involved in many cellular events from signaling cascades to epigenetic and transcriptional regulation. O-GlcNAcylation is a conserved nutrient-dependent process involving two enzymes, with O-GlcNAc transferase (OGT) adding O-GlcNAc and with O-GlcNAcase (OGA) removing it in a manner that’s protein- and context-dependent. O-GlcNAcylation is essential for epigenetic regulation of gene expression through its action on Polycomb and Trithorax and COMPASS complexes. However, the important role of O-GlcNAc in adult life and health span has been largely unexplored, mainly due the lack of available model systems. Cataloging the O-GlcNAc proteome has proven useful in understanding the biology of this modification in vivo. In this study, we leveraged a recently developed oga knockout fly mutant to identify the O-GlcNAcylated proteins in adult Drosophilamelanogaster. The adult O-GlcNAc proteome revealed many proteins related to cell and organismal growth, development, differentiation, and epigenetics. We identified many O-GlcNAcylated proteins that play a role in increased growth and decreased longevity, including HCF, SIN3A, LOLA, KISMET, ATX2, SHOT, and FOXO. Interestingly, oga mutant flies are larger and have a shorter life span compared to wild type flies, suggesting increased O-GlcNAc results in increased growth. Our results suggest that O-GlcNAc alters the function of many proteins related to transcription, epigenetic modification and signaling pathways that regulate growth rate and longevity. Therefore, our findings highlight the importance of O-GlcNAc in growth and life span in adult Drosophila.
- Published
- 2021
- Full Text
- View/download PDF
25. Spatial separation of the cyanogenic β-glucosidase ZfBGD2 and cyanogenic glucosides in the haemolymph of Zygaena larvae facilitates cyanide release
- Author
-
Stefan Pentzold, Mikael Kryger Jensen, Annemarie Matthes, Carl Erik Olsen, Bent Larsen Petersen, Henrik Clausen, Birger Lindberg Møller, Søren Bak, and Mika Zagrobelny
- Subjects
cyanogenesis ,β-glucosidase ,cyanogenic glucoside ,haemolymph ,caterpillar ,Science - Abstract
Low molecular weight compounds are typically used by insects and plants for defence against predators. They are often stored as inactive β-glucosides and kept separate from activating β-glucosidases. When the two components are mixed, the β-glucosides are hydrolysed releasing toxic aglucones. Cyanogenic plants contain cyanogenic glucosides and release hydrogen cyanide due to such a well-characterized two-component system. Some arthropods are also cyanogenic, but comparatively little is known about their system. Here, we identify a specific β-glucosidase (ZfBGD2) involved in cyanogenesis from larvae of Zygaena filipendulae (Lepidoptera, Zygaenidae), and analyse the spatial organization of cyanide release in this specialized insect. High levels of ZfBGD2 mRNA and protein were found in haemocytes by transcriptomic and proteomic profiling. Heterologous expression in insect cells showed that ZfBGD2 hydrolyses linamarin and lotaustralin, the two cyanogenic glucosides present in Z. filipendulae. Linamarin and lotaustralin as well as cyanide release were found exclusively in the haemoplasma. Phylogenetic analyses revealed that ZfBGD2 clusters with other insect β-glucosidases, and correspondingly, the ability to hydrolyse cyanogenic glucosides catalysed by a specific β-glucosidase evolved convergently in insects and plants. The spatial separation of the β-glucosidase ZfBGD2 and its cyanogenic substrates within the haemolymph provides the basis for cyanide release in Z. filipendulae. This spatial separation is similar to the compartmentalization of the two components found in cyanogenic plant species, and illustrates one similarity in cyanide-based defence in these two kingdoms of life.
- Published
- 2017
- Full Text
- View/download PDF
26. Expression of the O-Glycosylation Enzyme GalNAc-T3 in the Equatorial Segment Correlates with the Quality of Spermatozoa
- Author
-
Marie B. Nygaard, Amy S. Herlihy, Charlotte Jeanneau, John E. Nielsen, Eric Paul Bennett, Niels Jørgensen, Henrik Clausen, Ulla Mandel, Ewa Rajpert-De Meyts, and Kristian Almstrup
- Subjects
GalNAc-T3 ,GALNT3 ,Male fertility ,Semen quality ,Mucin-type O-linked glycosylation ,Spermatozoa ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
We question whether the expression of GalNAc-T3, the only known O-GalNAc-transferase present in germ cells, is correlated with qualitative and functional parameters of spermatozoa. We investigated the expression of GalNAc-T3 in ejaculated spermatozoa with immunocytochemistry in swim-up purified and acrosome-reacted spermatozoa from quality-control semen donors and in semen samples from 206 randomly selected men representing a broad spectrum of semen quality. Using donor ejaculates and immunofluorescence detection we found that expression of GalNAc-T3 and the presence of the immature O-glycans Tn and T localized to the equatorial segment of spermatozoa. The proportion of GalNAc-T3-positive spermatozoa in the ejaculate increased after swim-up and appeared unaffected by induction of acrosomal exocytosis. The fraction of spermatozoa with equatorial expression of GalNAc-T3 correlated with classical semen parameters (concentration p = 9 × 10−6, morphology p = 7 × 10−8, and motility p = 1.8 × 10−5) and was significantly lower in men with oligoteratoasthenozoospermia (p = 0.0048). In conclusion, GalNAc-T3 was highly expressed by motile spermatozoa and the expression correlated positively with the classical semen parameters. Therefore, GalNAc-T3 expression seems related to the quality of the spermatozoa, and we propose that reduced expression of GalNAc-T3 may lead to impaired O-glycosylation of proteins and thereby abnormal maturation and reduced functionality of the spermatozoa.
- Published
- 2018
- Full Text
- View/download PDF
27. Mucins and Truncated O-Glycans Unveil Phenotypic Discrepancies between Serous Ovarian Cancer Cell Lines and Primary Tumours
- Author
-
Ricardo Coelho, Lara Marcos-Silva, Nuno Mendes, Daniela Pereira, Catarina Brito, Francis Jacob, Catharina Steentoft, Ulla Mandel, Henrik Clausen, Leonor David, and Sara Ricardo
- Subjects
serous ovarian carcinomas ,ovarian cancer cell lines ,MUC16 ,MUC1 ,truncated O-glycans ,COSMC ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Optimal research results rely on the selection of cellular models capable of recapitulating the characteristics of primary tumours from which they originate. The expression of mucins (MUC16 and MUC1) and truncated O-glycans (Tn, STn and T) represents a characteristic footprint of serous ovarian carcinomas (SOCs). Therefore, selecting ovarian cancer (OVCA) cell lines that reflect this phenotype is crucial to explore the putative biological role of these biomarkers in the SOC setting. Here, we investigated a panel of OVCA cell lines commonly used as SOC models, and tested whether, when cultured in 2D and 3D conditions, these recapitulate the mucin and O-glycan expression profiles of SOCs. We further explored the role of truncating the O-glycosylation capacity in OVCAR3 cells through knockout of the COSMC chaperone, using in vitro and in vivo assays. We found that the majority of OVCA cell lines of serous origin do not share the mucin and truncated O-glycan footprint of SOCs, although 3D cultures showed a higher resemblance. We also found that genetic truncation of the O-glycosylation capacity of OVCAR3 cells did not enhance oncogenic features either in vitro or in vivo. This study underscores the importance of well-characterized cellular models to study specific features of ovarian cancer.
- Published
- 2018
- Full Text
- View/download PDF
28. Fucosylation and protein glycosylation create functional receptors for cholera toxin
- Author
-
Amberlyn M Wands, Akiko Fujita, Janet E McCombs, Jakob Cervin, Benjamin Dedic, Andrea C Rodriguez, Nicole Nischan, Michelle R Bond, Marcel Mettlen, David C Trudgian, Andrew Lemoff, Marianne Quiding-Järbrink, Bengt Gustavsson, Catharina Steentoft, Henrik Clausen, Hamid Mirzaei, Susann Teneberg, Ulf Yrlid, and Jennifer J Kohler
- Subjects
glycoprotein ,glycolipids/gangliosides ,endocytosis ,cholera ,epithelial cell ,toxins ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Cholera toxin (CT) enters and intoxicates host cells after binding cell surface receptors using its B subunit (CTB). The ganglioside (glycolipid) GM1 is thought to be the sole CT receptor; however, the mechanism by which CTB binding to GM1 mediates internalization of CT remains enigmatic. Here we report that CTB binds cell surface glycoproteins. Relative contributions of gangliosides and glycoproteins to CTB binding depend on cell type, and CTB binds primarily to glycoproteins in colonic epithelial cell lines. Using a metabolically incorporated photocrosslinking sugar, we identified one CTB-binding glycoprotein and demonstrated that the glycan portion of the molecule, not the protein, provides the CTB interaction motif. We further show that fucosylated structures promote CTB entry into a colonic epithelial cell line and subsequent host cell intoxication. CTB-binding fucosylated glycoproteins are present in normal human intestinal epithelia and could play a role in cholera.
- Published
- 2015
- Full Text
- View/download PDF
29. The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL.
- Author
-
Richard Beatson, Gjertrud Maurstad, Gianfranco Picco, Appitha Arulappu, Julia Coleman, Hans H Wandell, Henrik Clausen, Ulla Mandel, Joyce Taylor-Papadimitriou, Marit Sletmoen, and Joy M Burchell
- Subjects
Medicine ,Science - Abstract
Aberrant glycosylation occurs in the majority of human cancers and changes in mucin-type O-glycosylation are key events that play a role in the induction of invasion and metastases. These changes generate novel cancer-specific glyco-antigens that can interact with cells of the immune system through carbohydrate binding lectins. Two glyco-epitopes that are found expressed by many carcinomas are Tn (GalNAc-Ser/Thr) and STn (NeuAcα2,6GalNAc-Ser/Thr). These glycans can be carried on many mucin-type glycoproteins including MUC1. We show that the majority of breast cancers carry Tn within the same cell and in close proximity to extended glycan T (Galβ1,3GalNAc) the addition of Gal to the GalNAc being catalysed by the T synthase. The presence of active T synthase suggests that loss of the private chaperone for T synthase, COSMC, does not explain the expression of Tn and STn in breast cancer cells. We show that MUC1 carrying both Tn or STn can bind to the C-type lectin MGL and using atomic force microscopy show that they bind to MGL with a similar dead adhesion force. Tumour associated STn is associated with poor prognosis and resistance to chemotherapy in breast carcinomas, inhibition of DC maturation, DC apoptosis and inhibition of NK activity. As engagement of MGL in the absence of TLR triggering may lead to anergy, the binding of MUC1-STn to MGL may be in part responsible for some of the characteristics of STn expressing tumours.
- Published
- 2015
- Full Text
- View/download PDF
30. Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.
- Author
-
Caroline B Madsen, Kirstine Lavrsen, Catharina Steentoft, Malene B Vester-Christensen, Henrik Clausen, Hans H Wandall, and Anders Elm Pedersen
- Subjects
Medicine ,Science - Abstract
Membrane bound mucins are up-regulated and aberrantly glycosylated during malignant transformation in many cancer cells. This results in a negatively charged glycoprotein coat which may protect cancer cells from immune surveillance. However, only limited data have so far demonstrated the critical steps in glycan elongation that make aberrantly glycosylated mucins affect the interaction between cancer cells and cytotoxic effector cells of the immune system. Tn (GalNAc-Ser/Thr), STn (NeuAcα2-6GalNAc-Ser/Thr), T (Galβ1-3GalNAc-Ser/Thr), and ST (NeuAcα2-6Galβ1-3GalNAc-Ser/Thr) antigens are recognized as cancer associated truncated glycans, and are expressed in many adenocarcinomas, e.g. breast- and pancreatic cancer cells. To investigate the role of the cancer associated glycan truncations in immune-mediated killing we created glyco-engineered breast- and pancreatic cancer cells expressing only the shortest possible mucin-like glycans (Tn and STn). Glyco-engineering was performed by zinc finger nuclease (ZFN) knockout (KO) of the Core 1 enzyme chaperone COSMC, thereby preventing glycan elongation beyond the initial GalNAc residue in O-linked glycans. We find that COSMC KO in the breast and pancreatic cancer cell lines T47D and Capan-1 increases sensitivity to both NK cell mediated antibody-dependent cellular-cytotoxicity (ADCC) and cytotoxic T lymphocyte (CTL)-mediated killing. In addition, we investigated the association between total cell surface expression of MUC1/MUC16 and NK or CTL mediated killing, and observed an inverse correlation between MUC16/MUC1 expression and the sensitivity to ADCC and CTL-mediated killing. Together, these data suggest that up-regulation of membrane bound mucins protects cells from immune mediated killing, and that particular glycosylation steps, as demonstrated for glycan elongation beyond Tn and STn, can be important for fine tuning of the immune escape mechanisms in cancer cells.
- Published
- 2013
- Full Text
- View/download PDF
31. Correction: Glycan Elongation Beyond the Mucin Associated Tn Antigen Protects Tumor Cells from Immune-Mediated Killing.
- Author
-
Caroline B. Madsen, Kirstine Lavrsen, Catharina Steentoft, Malene B. Vester-Christensen, Henrik Clausen, Hans H. Wandall, and Anders Elm Pedersen
- Subjects
Medicine ,Science - Published
- 2013
- Full Text
- View/download PDF
32. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
- Author
-
Caroline B Madsen, Cecilie Petersen, Kirstine Lavrsen, Mikkel Harndahl, Søren Buus, Henrik Clausen, Anders E Pedersen, and Hans H Wandall
- Subjects
Medicine ,Science - Abstract
Aberrant glycosylation of mucins and other extracellular proteins is an important event in carcinogenesis and the resulting cancer associated glycans have been suggested as targets in cancer immunotherapy. We assessed the role of O-linked GalNAc glycosylation on antigen uptake, processing, and presentation on MHC class I and II molecules. The effect of GalNAc O-glycosylation was monitored with a model system based on ovalbumin (OVA)-MUC1 fusion peptides (+/- glycosylation) loaded onto dendritic cells co-cultured with IL-2 secreting OVA peptide-specific T cell hybridomas. To evaluate the in vivo response to a cancer related tumor antigen, Balb/c or B6.Cg(CB)-Tg(HLA-A/H2-D)2Enge/J (HLA-A2 transgenic) mice were immunized with a non-glycosylated or GalNAc-glycosylated MUC1 derived peptide followed by comparison of T cell proliferation, IFN-γ release, and antibody induction. GalNAc-glycosylation promoted presentation of OVA-MUC1 fusion peptides by MHC class II molecules and the MUC1 antigen elicited specific Ab production and T cell proliferation in both Balb/c and HLA-A2 transgenic mice. In contrast, GalNAc-glycosylation inhibited the presentation of OVA-MUC1 fusion peptides by MHC class I and abolished MUC1 specific CD8+ T cell responses in HLA-A2 transgenic mice. GalNAc glycosylation of MUC1 antigen therefore facilitates uptake, MHC class II presentation, and antibody response but might block the antigen presentation to CD8+ T cells.
- Published
- 2012
- Full Text
- View/download PDF
33. The SHDRA syndrome-associated gene TMEM260 encodes a protein-specific O-mannosyltransferase
- Author
-
Ida Signe Bohse Larsen, Lorenzo Povolo, Luping Zhou, Weihua Tian, Kasper Johansen Mygind, John Hintze, Chen Jiang, Verity Hartill, Katrina Prescott, Colin A. Johnson, Sureni V. Mullegama, Allyn McConkie-Rosell, Marie McDonald, Lars Hansen, Sergey Y. Vakhrushev, Katrine T. Schjoldager, Henrik Clausen, Thomas Worzfeld, Hiren J. Joshi, and Adnan Halim
- Subjects
Multidisciplinary ,glycosylation ,glycoproteomics ,plexin ,O-mannosylation ,congenital disorders of glycosylation - Abstract
Mutations in the TMEM260 gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown. We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains. Here, we report that the TMEM260 gene encodes an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains. We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models. Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis. Our findings add a new glycosylation pathway and gene to a growing group of congenital disorders of glycosylation.
- Published
- 2023
34. Supplementary Figure 1 from Aberrant Expression of Mucin Core Proteins and O-Linked Glycans Associated with Progression of Pancreatic Cancer
- Author
-
Michael A. Hollingsworth, Fang Yu, Henrik Clausen, Ulla Mandel, Hans H. Wandall, Audrey J. Lazenby, Dominick J. DiMaio, Erin M. Linde, Judy M. Anderson, and Neeley Remmers
- Abstract
PDF file - 248K, Supplementary Figure 1. (A) Simplified schematic of mucin type O-glycans analyzed in this report. Mucin-type O-linked glycans are initiated by the addition of an N-acetyl galactose sugar residue (the Tn epitope), which can be extended into the T antigen or core 3 structures, or Tn can be sialylated creating terminal STn that cannot be further extended. T antigen can be extended into core 2 structures that lead to the Lewis Blood Group antigens - LeX, SLeX, SLeC and sialyl Lewis A (the CA19-9 antigen, a widely utilized biomarker of adenocarcinoma progression). B & C - Representative immunohistochemical results for comparison of expression of mucin core proteins, glycans, and glycopeptides taken at 200x magnification. (B) Serial sections of primary tumor from autopsy patient 3 stained for indicated antigens. (C) Serial sections of liver metastasis from autopsy patient 20 for same antigens seen in primary tumor.
- Published
- 2023
35. Data from Aberrant Expression of Mucin Core Proteins and O-Linked Glycans Associated with Progression of Pancreatic Cancer
- Author
-
Michael A. Hollingsworth, Fang Yu, Henrik Clausen, Ulla Mandel, Hans H. Wandall, Audrey J. Lazenby, Dominick J. DiMaio, Erin M. Linde, Judy M. Anderson, and Neeley Remmers
- Abstract
Purpose: Mucin expression is a common feature of most adenocarcinomas and features prominently in current attempts to improve diagnosis and therapy for pancreatic cancer and other adenocarcinomas. We investigated the expression of a number of mucin core proteins and associated O-linked glycans expressed in pancreatic adenocarcinoma—sialyl Tn (STn), Tn, T antigen, sialyl Lewis A (CA19-9), sialyl Lewis C (SLeC), Lewis X (LeX), and sialyl LeX (SLeX)—during the progression of pancreatic cancer from early stages to metastatic disease.Experimental Design: Immunohistochemical analyses of mucin and associated glycan expression on primary tumor and liver metastatic tumor samples were conducted with matched sets of tissues from 40 autopsy patients diagnosed with pancreatic adenocarcinoma, 14 surgically resected tissue samples, and 8 normal pancreata.Results: There were significant changes in mucin expression patterns throughout disease progression. MUC1 and MUC4 were differentially glycosylated as the disease progressed from early pancreatic intraepithelial neoplasias to metastatic disease. De novo expression of several mucins correlated with increased metastasis indicating a potentially more invasive phenotype, and we show the expression of MUC6 in acinar cells undergoing acinar to ductal metaplasia. A “cancer field-effect” that included changes in mucin protein expression and glycosylation in the adjacent normal pancreas was also seen.Conclusions: There are significant alterations in mucin expression and posttranslational processing during progression of pancreatic cancer from early lesions to metastasis. The results are presented in the context of how mucins influence the biology of tumor cells and their microenvironment during progression of pancreatic cancer. Clin Cancer Res; 19(8); 1981–93. ©2013 AACR.
- Published
- 2023
36. Supplementary Figure 2 from Aberrant Expression of Mucin Core Proteins and O-Linked Glycans Associated with Progression of Pancreatic Cancer
- Author
-
Michael A. Hollingsworth, Fang Yu, Henrik Clausen, Ulla Mandel, Hans H. Wandall, Audrey J. Lazenby, Dominick J. DiMaio, Erin M. Linde, Judy M. Anderson, and Neeley Remmers
- Abstract
PDF file - 320K, Supplementary Figure 2. Representative immunohistochemical results for comparison of cancer fieldeffects in autopsy and resection tissue samples from the same patients. Two different autopsy patients who underwent surgical resection are presented. Serial sections stained for the antigens indicated are shown in the resection tissue samples alongside the autopsy samples of their primary tumors. 200x magnification.
- Published
- 2023
37. Supplementary Figure Legend from Aberrant Expression of Mucin Core Proteins and O-Linked Glycans Associated with Progression of Pancreatic Cancer
- Author
-
Michael A. Hollingsworth, Fang Yu, Henrik Clausen, Ulla Mandel, Hans H. Wandall, Audrey J. Lazenby, Dominick J. DiMaio, Erin M. Linde, Judy M. Anderson, and Neeley Remmers
- Abstract
PDF file - 25K
- Published
- 2023
38. Supplementary Results, Figures 1-2, Table 1 from Cancer Biomarkers Defined by Autoantibody Signatures to Aberrant O-Glycopeptide Epitopes
- Author
-
Henrik Clausen, Joy Burchell, Joyce Taylor-Papadimitriou, Michael A. Hollingsworth, Phil O. Livingston, Govind Ragupathi, Ulla Mandel, Eric P. Bennett, Johannes W. Pedersen, Mads A. Tarp, Ola Blixt, and Hans H. Wandall
- Abstract
Supplementary Results, Figures 1-2, Table 1 from Cancer Biomarkers Defined by Autoantibody Signatures to Aberrant O-Glycopeptide Epitopes
- Published
- 2023
39. UV light-induced spatial loss of sialic acid capping using a photoactivatable sialyltransferase inhibitor
- Author
-
Sam Moons, Daniël L.A.H. Hornikx, Mikkel M Andersen, Johan Pijnenborg, Matteo Calzari, Paul White, Yoshiki Narimatsu, Henrik Clausen, Hans Wandall, Thomas Boltje, and Christian Büll
- Subjects
Chemistry (miscellaneous) ,Bio-Molecular Chemistry ,Synthetic Organic Chemistry ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Molecular Biology ,Biochemistry ,Physical Organic Chemistry - Abstract
Sialic acids cap glycans displayed on mammalian glycoproteins and glycolipids and mediate many glycan-receptor interactions. Sialoglycans play a role in diseases such as cancer and infections where they facilitate immune...
- Published
- 2023
40. The incorrect use of CD75 as a synonym for ST6GAL1 has fostered the expansion of commercial 'ST6GAL1' antibodies that do not recognize ST6GAL1
- Author
-
Barnita Haldar, Jihye Hwang, Yoshiki Narimatsu, Henrik Clausen, and Susan L Bellis
- Subjects
Epitopes ,Mice ,Urinary Bladder Neoplasms ,Antigens, CD ,Polysaccharides ,Animals ,Humans ,Biochemistry ,GlycoForum - Technical Note ,Sialyltransferases - Abstract
The ST6GAL1 Golgi sialyltransferase is upregulated in many human malignancies, however, detection of ST6GAL1 protein in cancer tissues has been hindered by the prior lack of antibodies. Recently, numerous commercial antibodies for ST6GAL1 have become available, however, many of these do not, in fact, recognize ST6GAL1. Decades ago, the CD75 cell-surface epitope was mistakenly suggested to be the same molecule as ST6GAL1. While this was rapidly disproven, the use of CD75 as a synonym for ST6GAL1 has persisted, particularly by companies selling “ST6GAL1” antibodies. CD75 is reportedly a sialylated epitope which appears to encompass a range of glycan structures and glycan carriers. In this study, we evaluated the LN1 and ZB55 monoclonal antibodies, which are advertised as ST6GAL1 antibodies but were initially developed as CD75-recognizing antibodies (neither was raised against ST6GAL1 as the immunogen). Importantly, the LN1 and ZB55 antibodies have been widely used by investigators, as well as the Human Protein Atlas database, to characterize ST6GAL1 expression. Herein, we used cell and mouse models with controlled expression of ST6GAL1 to compare LN1 and ZB55 with an extensively validated polyclonal antibody to ST6GAL1. We find that LN1 and ZB55 do not recognize ST6GAL1, and furthermore, these 2 antibodies recognize different targets. Additionally, we utilized the well-validated ST6GAL1 antibody to determine that ST6GAL1 is overexpressed in bladder cancer, a finding that contradicts prior studies which employed LN1 to suggest ST6GAL1 is downregulated in bladder cancer. Collectively, our studies underscore the need for careful validation of antibodies purported to recognize ST6GAL1.
- Published
- 2022
41. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer
- Author
-
Catharina Steentoft, Jen Jen Yeh, Hye Rim Lee, Fang Qiu, Lara Marcos-Silva, Benjamin J. Swanson, Ulla Mandel, Michael A. Hollingsworth, Kelly A. O'Connell, Xiang Liu, Fang Yu, Henrik Clausen, Hans H. Wandall, Xianlu L. Peng, Divya Thomas, Kenneth P. Olive, Satish Sagar, James A. Grunkemeyer, Paul M. Grandgenett, Thomas C. Caffrey, Hans Carlo Maurer, Prakash Radhakrishnan, and Ragupathy Madiyalakan
- Subjects
endocrine system diseases ,Carcinogenesis ,Adenocarcinoma ,Biology ,medicine.disease_cause ,Malignancy ,Metastasis ,Mice ,03 medical and health sciences ,ErbB Receptors ,0302 clinical medicine ,Epidermal growth factor ,Cell Line, Tumor ,Pancreatic cancer ,Drug Discovery ,Genetics ,medicine ,Animals ,Humans ,Protein Isoforms ,Neoplasm Metastasis ,Receptor ,Molecular Biology ,Protein kinase B ,Cell Proliferation ,030304 developmental biology ,Pharmacology ,0303 health sciences ,Antibodies, Monoclonal ,Membrane Proteins ,medicine.disease ,Gene Expression Regulation, Neoplastic ,CA-125 Antigen ,030220 oncology & carcinogenesis ,Disease Progression ,Cancer research ,Molecular Medicine ,Original Article ,Carcinoma, Pancreatic Ductal ,Signal Transduction - Abstract
Aberrant expression of CA125/MUC16 is associated with pancreatic ductal adenocarcinoma (PDAC) progression and metastasis. However, knowledge of the contribution of MUC16 to pancreatic tumorigenesis is limited. Here, we show that MUC16 expression is associated with disease progression, basal-like and squamous tumor subtypes, increased tumor metastasis, and short-term survival of PDAC patients. MUC16 enhanced tumor malignancy through the activation of AKT and GSK3β oncogenic signaling pathways. Activation of these oncogenic signaling pathways resulted in part from increased interactions between MUC16 and epidermal growth factor (EGF)-type receptors, which were enhanced for aberrant glycoforms of MUC16. Treatment of PDAC cells with monoclonal antibody (mAb) AR9.6 significantly reduced MUC16-induced oncogenic signaling. mAb AR9.6 binds to a unique conformational epitope on MUC16, which is influenced by O-glycosylation. Additionally, treatment of PDAC tumor-bearing mice with either mAb AR9.6 alone or in combination with gemcitabine significantly reduced tumor growth and metastasis. We conclude that the aberrant expression of MUC16 enhances PDAC progression to an aggressive phenotype by modulating oncogenic signaling through ErbB receptors. Anti-MUC16 mAb AR9.6 blocks oncogenic activities and tumor growth and could be a novel immunotherapeutic agent against MUC16-mediated PDAC tumor malignancy.
- Published
- 2021
42. Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy
- Author
-
Senlian Hong, Jie Li, John R. Yates, Chenhua Yu, Xing Chen, Bo Cheng, Digantkumar Chapla, Emily Rodrigues, Yoshiki Narimatsu, Henrik Clausen, Yujie Shi, Kelly W. Moremen, Peng Wang, Yuanhui Ma, Weiqian Cao, Peng Wu, James C. Paulson, and Matthew S. Macauley
- Subjects
CD22 ligands ,Lymphoma, B-Cell ,Sialic Acid Binding Ig-like Lectin 2 ,Mice, SCID ,Sialic acid binding ,Ligands ,010402 general chemistry ,chemoenzymatic glycan editing ,01 natural sciences ,Article ,Catalysis ,sLeX ,Mice, Inbred NOD ,Polysaccharides ,immune system diseases ,Cell Line, Tumor ,hemic and lymphatic diseases ,Carbohydrate Conformation ,medicine ,Animals ,Humans ,B-cell lymphoma ,CD20 ,B-lymphoma ,biology ,010405 organic chemistry ,Chemistry ,E-selectin ,CD22 ,SIGLEC ,Neoplasms, Experimental ,General Chemistry ,medicine.disease ,0104 chemical sciences ,Killer Cells, Natural ,HEK293 Cells ,Cell killing ,Metabolic Engineering ,Cancer cell ,biology.protein ,Cancer research ,Antibody - Abstract
CD22, a member of Siglec family of sialic acid binding proteins, has restricted expression on B cells. Antibody-based agents targeting CD22 or CD20 on B lymphoma and leukemia cells exhibit clinical efficacy for treating these malignancies, but also attack normal B cells leading to immune deficiency. Here, we report a chemoenzymatic glycocalyx editing strategy to introduce high-affinity and specific CD22 ligands onto NK-92MI and cytokine-induced natural killer cells to achieve tumor-specific CD22 targeting. These CD22-ligand modified cells exhibited significantly enhanced tumor cell binding and killing in vitro without harming healthy B cells. For effective lymphoma cell killing in vivo, we further functionalized CD22 ligand-modified NK-92MI cells with the E-selectin ligand sialyl Lewis X to promote trafficking to bone marrow. The dual-functionalized cells resulted in the efficient suppression of B lymphoma in a xenograft model. Our results suggest that nature killer cells modified with glycan ligands to CD22 and selectins promote both targeted killing of B lymphoma cells and improved trafficking to sites where the cancer cells reside, respectively.
- Published
- 2020
43. Global view of human protein glycosylation pathways and functions
- Author
-
Hiren J. Joshi, Katrine T. Schjoldager, Yoshiki Narimatsu, and Henrik Clausen
- Subjects
chemistry.chemical_classification ,0303 health sciences ,animal structures ,Glycosylation ,In silico ,Metabolic network ,macromolecular substances ,Cell Biology ,Computational biology ,Biology ,Proteomics ,carbohydrates (lipids) ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Genome editing ,chemistry ,Proteome ,lipids (amino acids, peptides, and proteins) ,Glycoprotein ,Molecular Biology ,030217 neurology & neurosurgery ,030304 developmental biology ,Genetic screen - Abstract
Glycosylation is the most abundant and diverse form of post-translational modification of proteins that is common to all eukaryotic cells. Enzymatic glycosylation of proteins involves a complex metabolic network and different types of glycosylation pathways that orchestrate enormous amplification of the proteome in producing diversity of proteoforms and its biological functions. The tremendous structural diversity of glycans attached to proteins poses analytical challenges that limit exploration of specific functions of glycosylation. Major advances in quantitative transcriptomics, proteomics and nuclease-based gene editing are now opening new global ways to explore protein glycosylation through analysing and targeting enzymes involved in glycosylation processes. In silico models predicting cellular glycosylation capacities and glycosylation outcomes are emerging, and refined maps of the glycosylation pathways facilitate genetic approaches to address functions of the vast glycoproteome. These approaches apply commonly available cell biology tools, and we predict that use of (single-cell) transcriptomics, genetic screens, genetic engineering of cellular glycosylation capacities and custom design of glycoprotein therapeutics are advancements that will ignite wider integration of glycosylation in general cell biology.
- Published
- 2020
44. ER-resident oxidoreductases are glycosylated and trafficked to the cell surface to promote matrix degradation by tumour cells
- Author
-
Ruth McDowall, Anh Tuan Nguyen, Martin J. Humphries, Son Le Tran, Frederic Bard, Manon Ros, Sergey Y. Vakhrushev, Frédéric Saltel, Henrik Clausen, Joanne Chia, and Xavier Le Guezennec
- Subjects
Male ,Glycosylation ,Lung Neoplasms ,Calnexin ,Cell ,Protein Disulfide-Isomerases ,Mice, Nude ,Breast Neoplasms ,Matrix (biology) ,Endoplasmic Reticulum ,Extracellular matrix ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Cell Movement ,Cell Line, Tumor ,medicine ,Extracellular ,Animals ,Neoplasm Invasiveness ,030304 developmental biology ,Mice, Inbred BALB C ,0303 health sciences ,Chemistry ,Endoplasmic reticulum ,Liver Neoplasms ,Cell Biology ,Xenograft Model Antitumor Assays ,Extracellular Matrix ,Cell biology ,Mice, Inbred C57BL ,Protein Transport ,medicine.anatomical_structure ,Cell culture ,alpha-Galactosidase ,030220 oncology & carcinogenesis ,Podosomes ,Proteolysis ,NIH 3T3 Cells ,Female - Abstract
Tumour growth and invasiveness require extracellular matrix (ECM) degradation and are stimulated by the GALA pathway, which induces protein O-glycosylation in the endoplasmic reticulum (ER). ECM degradation requires metalloproteases, but whether other enzymes are required is unclear. Here, we show that GALA induces the glycosylation of the ER-resident calnexin (Cnx) in breast and liver cancer. Glycosylated Cnx and its partner ERp57 are trafficked to invadosomes, which are sites of ECM degradation. We find that disulfide bridges are abundant in connective and liver ECM. Cell surface Cnx-ERp57 complexes reduce these extracellular disulfide bonds and are essential for ECM degradation. In vivo, liver cancer cells but not hepatocytes display cell surface Cnx. Liver tumour growth and lung metastasis of breast and liver cancer cells are inhibited by anti-Cnx antibodies. These findings uncover a moonlighting function of Cnx-ERp57 at the cell surface that is essential for ECM breakdown and tumour development.
- Published
- 2020
45. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides
- Author
-
Preeti Sharma, Venkata V.V.R. Marada, Steven P. Wolf, Qi Cai, Karin Schreiber, David M. Kranz, Hans Schreiber, Henrik Clausen, Yanran He, and Monika Kizerwetter
- Subjects
Models, Molecular ,Protein Conformation ,T-Lymphocytes ,T cell ,Tn antigen ,Yeast display ,Antibodies ,CD19 ,Epitope ,Epitopes ,Mice ,Antigen ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Antigens, Tumor-Associated, Carbohydrate ,Amino Acid Sequence ,Receptors, Chimeric Antigen ,Multidisciplinary ,biology ,Chemistry ,Biological Sciences ,Chimeric antigen receptor ,Cell biology ,medicine.anatomical_structure ,Mutation ,biology.protein ,Directed Molecular Evolution ,Antibody - Abstract
The potency of adoptive T cell therapies targeting the cell surface antigen CD19 has been demonstrated in hematopoietic cancers. It has been difficult to identify appropriate targets in nonhematopoietic tumors, but one class of antigens that have shown promise is aberrant O-glycoprotein epitopes. It has long been known that dysregulated synthesis of O-linked (threonine or serine) sugars occurs in many cancers, and that this can lead to the expression of cell surface proteins containing O-glycans comprised of a single N-acetylgalactosamine (GalNAc, known as Tn antigen) rather than the normally extended carbohydrate. Previously, we used the scFv fragment of antibody 237 as a chimeric antigen receptor (CAR) to mediate recognition of mouse tumor cells that bear its cognate Tn-glycopeptide epitope in podoplanin, also called OTS8. Guided by the structure of the 237 Fab:Tn-OTS8-glycopeptide complex, here we conducted a deep mutational scan showing that residues flanking the Tn-glycan contributed significant binding energy to the interaction. Design of 237-scFv libraries in the yeast display system allowed us to isolate scFv variants with higher affinity for Tn-OTS8. Selection with a noncognate human antigen, Tn-MUC1, yielded scFv variants that were broadly reactive with multiple Tn-glycoproteins. When configured as CARs, engineered T cells expressing these scFv variants showed improved activity against mouse and human cancer cell lines defective in O-linked glycosylation. This strategy provides CARs with Tn-peptide specificities, all based on a single scFv scaffold, that allows the same CAR to be tested for toxicity in mice and efficacy against mouse and human tumors.
- Published
- 2020
46. Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation
- Author
-
Ramon Hurtado-Guerrero, Ana García-García, Erandi Lira-Navarrete, Earnest James Paul Daniel, Matilde de las Rivas, Thomas A. Gerken, and Henrik Clausen
- Subjects
Threonine ,Glycosylation ,Stereochemistry ,Peptide ,Biochemistry ,Isozyme ,chemistry.chemical_compound ,parasitic diseases ,Glycosyltransferase ,Serine ,Humans ,Glycan Synthesis ,Peptide sequence ,chemistry.chemical_classification ,biology ,Mucins ,Substrate (chemistry) ,Active site ,Acceptor ,Isoenzymes ,carbohydrates (lipids) ,chemistry ,biology.protein ,N-Acetylgalactosaminyltransferases ,lipids (amino acids, peptides, and proteins) - Abstract
A family of polypeptide GalNAc-transferases (GalNAc-Ts) initiates mucin-type O-glycosylation, transferring GalNAc onto hydroxyl groups of Ser and Thr residues of target substrates. The 20 GalNAc-T isoenzymes in humans are classified into nine subfamilies according to sequence similarity. GalNAc-Ts select their sites of glycosylation based on weak and overlapping peptide sequence motifs, as well prior substrate O-GalNAc glycosylation at sites both remote (long-range) and neighboring (short-range) the acceptor. Together, these preferences vary among GalNAc-Ts imparting each isoenzyme with its own unique specificity. Studies on the first identified GalNAc-Ts showed Thr acceptors were preferred over Ser acceptors; however studies comparing Thr vs. Ser glycosylation across the GalNAc-T family are lacking. Using a series of identical random peptide substrates, with single Thr or Ser acceptor sites, we determined the rate differences (Thr/Ser rate ratio) between Thr and Ser substrate glycosylation for 12 isoenzymes (representing 7 GalNAc-T subfamilies). These Thr/Ser rate ratios varied across subfamilies, ranging from ~2 to ~18 (for GalNAc-T4/GalNAc-T12 and GalNAc-T3/GalNAc-T6, respectively), while nearly identical Thr/Ser rate ratios were observed for isoenzymes within subfamilies. Furthermore, the Thr/Ser rate ratios did not appreciably vary over a series of fixed sequence substrates of different relative activities, suggesting the ratio is a constant for each isoenzyme against single acceptor substrates. Finally, based on GalNAc-T structures, the different Thr/Ser rate ratios likely reflect differences in the strengths of the Thr acceptor methyl group binding to the active site pocket. With this work, another activity that further differentiates substrate specificity among the GalNAc-Ts has been identified.
- Published
- 2020
47. A mutation map for human glycoside hydrolase genes
- Author
-
Lars Hansen, Bernard Henrissat, Torben Hansen, Hans H. Wandall, Mitali A. Tambe, Hudson H. Freeze, Hassan Y. Naim, Eric P. Bennett, Oluf Pedersen, Diab M Husein, Birthe Gericke, Henrik Clausen, University of Copenhagen = Københavns Universitet (UCPH), Hannover Medical School [Hannover] (MHH), Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR), Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Sanford Burnham Prebys Medical Discovery Institute, Architecture et fonction des macromolécules biologiques (AFMB), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Danmarks Grundforskningsfond DNRF107Lundbeckfonden R223-2016-563 R317-2019-225United States Department of Health & Human Services National Institutes of Health (NIH) - USA R01 DK099551, University of Copenhagen = Københavns Universitet (KU), and University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU)
- Subjects
Nonsynonymous substitution ,Glycoside Hydrolases ,Proteome ,[SDV]Life Sciences [q-bio] ,medicine.disease_cause ,Biochemistry ,Regular Manuscripts ,03 medical and health sciences ,0302 clinical medicine ,Glycosyltransferase ,medicine ,Humans ,Glycoside hydrolase ,Gene ,030304 developmental biology ,Genetics ,chemistry.chemical_classification ,0303 health sciences ,Mutation ,biology ,Phenotype ,congenital disorders of glycoside hydrolysis ,3. Good health ,chemistry ,biology.protein ,WES ,Human genome ,nsSNV ,Glycoprotein ,030217 neurology & neurosurgery - Abstract
Glycoside hydrolases (GHs) are found in all domains of life, and at least 87 distinct genes encoding proteins related to GHs are found in the human genome. GHs serve diverse functions from digestion of dietary polysaccharides to breakdown of intracellular oligosaccharides, glycoproteins, proteoglycans and glycolipids. Congenital disorders of GHs (CDGHs) represent more than 30 rare diseases caused by mutations in one of the GH genes. We previously used whole-exome sequencing of a homogenous Danish population of almost 2000 individuals to probe the incidence of deleterious mutations in the human glycosyltransferases (GTs) and developed a mutation map of human GT genes (GlyMAP-I). While deleterious disease-causing mutations in the GT genes were very rare, and in many cases lethal, we predicted deleterious mutations in GH genes to be less rare and less severe given the higher incidence of CDGHs reported worldwide. To probe the incidence of GH mutations, we constructed a mutation map of human GH-related genes (GlyMAP-II) using the Danish WES data, and correlating this with reported disease-causing mutations confirmed the higher prevalence of disease-causing mutations in several GH genes compared to GT genes. We identified 76 novel nonsynonymous single-nucleotide variations (nsSNVs) in 32 GH genes that have not been associated with a CDGH phenotype, and we experimentally validated two novel potentially damaging nsSNVs in the congenital sucrase-isomaltase deficiency gene, SI. Our study provides a global view of human GH genes and disease-causing mutations and serves as a discovery tool for novel damaging nsSNVs in CDGHs.
- Published
- 2020
48. Endoplasmic reticulum transmembrane protein TMTC3 contributes to O-mannosylation of E-cadherin, cellular adherence, and embryonic gastrulation
- Author
-
Ida Signe Bohse Larsen, Adnan Halim, Jill B. Graham, Johan C. Sunryd, Dominque Alfandari, Ketan Mathavan, Daniel N. Hebert, Emma Weir, Hélène Cousin, and Henrik Clausen
- Subjects
Glycosylation ,Biosynthesis and Biodegradation ,Biology ,Endoplasmic Reticulum ,03 medical and health sciences ,chemistry.chemical_compound ,Xenopus laevis ,0302 clinical medicine ,Chlorocebus aethiops ,Cell Adhesion ,Animals ,Humans ,Molecular Biology ,030304 developmental biology ,Neurons ,0303 health sciences ,COS cells ,Cadherin ,Endoplasmic reticulum ,HEK 293 cells ,Gastrulation ,Membrane Proteins ,Cell Biology ,Articles ,Cadherins ,Transmembrane protein ,Cell biology ,HEK293 Cells ,chemistry ,Membrane protein ,COS Cells ,Mutation ,Carrier Proteins ,Cell Adhesion Molecules ,Mannose ,030217 neurology & neurosurgery - Abstract
Protein glycosylation plays essential roles in protein structure, stability, and activity such as cell adhesion. The cadherin superfamily of adhesion molecules carry O-linked mannose glycans at conserved sites and it was recently demonstrated that the transmembrane and tetratricopeptide repeat-containing proteins 1-4 (TMTC1-4) gene products contribute to the addition of these O-linked mannoses. Here, biochemical, cell biological, and organismal analysis was used to determine that TMTC3 supports the O-mannosylation of E-cadherin, cellular adhesion, and embryonic gastrulation. Using genetically engineered cells lacking all four TMTC genes, overexpression of TMTC3 rescued O-linked glycosylation of E-cadherin and cell adherence. The knockdown of the Tmtcs in Xenopus laevis embryos caused a delay in gastrulation that was rescued by the addition of human TMTC3. Mutations in TMTC3 have been linked to neuronal cell migration diseases including Cobblestone lissencephaly. Analysis of TMTC3 mutations associated with Cobblestone lissencephaly found that three of the variants exhibit reduced stability and missence mutations were unable to complement TMTC3 rescue of gastrulation in Xenopus embryo development. Our study demonstrates that TMTC3 regulates O-linked glycosylation and cadherin-mediated adherence, providing insight into its effect on cellular adherence and migration, as well the basis of TMTC3-associated Cobblestone lissencephaly.
- Published
- 2020
49. Meeting report on 14th Jenner Glycobiology and Medicine Symposium: glycobiology in immunology, medicine, and clinical practice
- Author
-
Roisin O’Flaherty, Ghislain Opdenakker, Henrik Clausen, Rita Gerardy-Schahn, Claudine Kieda, Celso A Reis, Pauline M Rudd, Azita Sadrieh, and John Axford
- Subjects
Biochemistry & Molecular Biology ,Science & Technology ,Life Sciences & Biomedicine ,Biochemistry - Abstract
ispartof: GLYCOBIOLOGY vol:32 issue:6 pages:458-459 ispartof: location:England status: published
- Published
- 2022
50. Exploring the glycosylation of mucins by use of O-glycodomain reporters recombinantly expressed in glycoengineered HEK293 cells
- Author
-
Andriana Konstantinidi, Rebecca Nason, Tomislav Čaval, Lingbo Sun, Daniel M. Sørensen, Sanae Furukawa, Zilu Ye, Renaud Vincentelli, Yoshiki Narimatsu, Sergey Y. Vakhrushev, and Henrik Clausen
- Subjects
Glycosylation ,Sheep ,Mucins ,Cell Biology ,Biochemistry ,Recombinant Proteins ,Mucins/metabolism ,HEK293 Cells ,Protein Domains ,Polysaccharides ,Recombinant Proteins/genetics ,Animals ,Humans ,Polysaccharides/genetics ,Amino Acid Sequence ,Molecular Biology - Abstract
Mucins and glycoproteins with mucin-like regions contain densely O-glycosylated domains often found in tandem repeat (TR) sequences. These O-glycodomains have traditionally been difficult to characterize because of their resistance to proteolytic digestion, and knowledge of the precise positions of O-glycans is particularly limited for these regions. Here, we took advantage of a recently developed glycoengineered cell-based platform for the display and production of mucin TR reporters with custom-designed O-glycosylation to characterize O-glycodomains derived from mucins and mucin-like glycoproteins. We combined intact mass and bottom-up site-specific analysis for mapping O-glycosites in the mucins, MUC2, MUC20, MUC21, protein P-selectin-glycoprotein ligand 1, and proteoglycan syndecan-3. We found that all the potential Ser/Thr positions in these O-glycodomains were O-glycosylated when expressed in human embryonic kidney 293 SimpleCells (Tn-glycoform). Interestingly, we found that all potential Ser/Thr O-glycosites in TRs derived from secreted mucins and most glycosites from transmembrane mucins were almost fully occupied, whereas TRs from a subset of transmembrane mucins were less efficiently processed. We further used the mucin TR reporters to characterize cleavage sites of glycoproteases StcE (secreted protease of C1 esterase inhibitor from EHEC) and BT4244, revealing more restricted substrate specificities than previously reported. Finally, we conducted a bottom-up analysis of isolated ovine submaxillary mucin, which supported our findings that mucin TRs in general are efficiently O-glycosylated at all potential glycosites. This study provides insight into O-glycosylation of mucins and mucin-like domains, and the strategies developed open the field for wider analysis of native mucins.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.